Eli Lilly Weight Loss Drug - Search News

Zepbound Tops Wegovy for Weight Loss

MarketWatch on MSN · 4h

Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.

USA Today · 5h

Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

Barron's on MSN · 7h

Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly said in a statement Wednesday. On average, Zepbound led to a superior weight loss of 20.

7h

Zepbound leads to more weight loss than Wegovy, new study finds

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

1d

Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results